HNSA — Hansa Biopharma AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.92bn
- SEK2.69bn
- SEK171.32m
Annual cashflow statement for Hansa Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -423 | -548 | -611 | -832 | -807 |
| Depreciation | |||||
| Non-Cash Items | 43.8 | 56.4 | 71.4 | 18 | 153 |
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 81.1 | 2.12 | 25 | 38.3 | -48.5 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -290 | -481 | -503 | -756 | -675 |
| Capital Expenditures | -0.294 | -2.4 | -3.33 | -0.284 | -0.116 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 183 | 0 | 233 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 183 | -2.4 | 229 | -0.284 | -0.116 |
| Financing Cash Flow Items | -0.001 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,066 | -4.86 | 1,118 | -7.54 | 347 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 958 | -488 | 845 | -764 | -327 |